Literature DB >> 8750369

Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers.

I H Benedek1, A S Joshi, H J Pieniaszek, S Y King, D M Kornhauser.   

Abstract

Data describing the pharmacokinetics and pharmacodynamics of low dose aspirin (acetylsalicylic acid; ASA) are limited. This single-center study was designed to determine the rate and extent of oral absorption of 80-mg ASA tablets in healthy, young male subjects and to assess the intra- and inter-subject variability of ASA pharmacokinetics and platelet aggregation effects. Ten subjects each received a single, open-label, oral 80-mg ASA dose on three separate days. Each dose was separated by a 2-week washout interval. Blood samples for pharmacokinetic determinations of ASA and its metabolite, salicylic acid (SA) and platelet aggregation studies were obtained at scheduled timepoints before and up to 24 hours after each dose. Peak plasma ASA levels of 1 microgram/mL were achieved within 30 minutes. Peak plasma SA levels of approximately 4 micrograms/mL were attained in 1 hour. The terminal half-lives (t1/2) of ASA and SA were 0.4 and 2.1 hours, respectively. Both ASA and SA pharmacokinetics and the platelet aggregation response to ASA exhibited considerable intra- and inter-subject variability. Inhibition of platelet aggregation was found to relate with ASA area under the plasma concentration versus time curve (AUC).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8750369     DOI: 10.1002/j.1552-4604.1995.tb04044.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  23 in total

Review 1.  Platelet PlA2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics.

Authors:  P J Goldschmidt-Clermont; C M Roos; G E Cooke
Journal:  J Thromb Thrombolysis       Date:  1999-08       Impact factor: 2.300

2.  In vitro bleeding test with PFA-100-aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease.

Authors:  A J Peters; M Borries; F Gradaus; T W Jax; F C Schoebel; B E Strauer
Journal:  J Thromb Thrombolysis       Date:  2001-12       Impact factor: 2.300

Review 3.  Aspirin in patients with coronary artery disease: is it simply irresistible?

Authors:  G V Nair; C J Davis; M E McKenzie; D R Lowry; V L Serebruany
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

4.  Aspirin as a COX inhibitor and anti-inflammatory drug in human skeletal muscle.

Authors:  Stephen M Ratchford; Kaleen M Lavin; Ryan K Perkins; Bozena Jemiolo; Scott W Trappe; Todd A Trappe
Journal:  J Appl Physiol (1985)       Date:  2017-07-13

Review 5.  Aspirin resistance - does it clinically matter?

Authors:  Karsten Schrör; T Hohlfeld; A-A Weber
Journal:  Clin Res Cardiol       Date:  2006-08-16       Impact factor: 5.460

6.  The evaluation method for antiplatelet effect of acetylsalicylic acid.

Authors:  Haruko Yokoyama; Takashi Mastumura; Shinji Soeda; Yuji Suzuki; Masayuki Watanabe; Emiko Kashiwakura; Takayuki Saso; Noriyuki Ikeda; Kentaro Tokuoka; Yasuhisa Kitagawa; Yasuhiko Yamada
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-12-22       Impact factor: 2.441

Review 7.  Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events.

Authors:  Joonseok Kim; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

Review 8.  Impairment of aspirin antiplatelet effects by non-opioid analgesic medication.

Authors:  Amin Polzin; Thomas Hohlfeld; Malte Kelm; Tobias Zeus
Journal:  World J Cardiol       Date:  2015-07-26

Review 9.  Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents.

Authors:  Parth J Parekh; Edward C Oldfield; David A Johnson
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

10.  Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action.

Authors:  D Taubert; R Berkels; N Grosser; H Schröder; D Gründemann; E Schömig
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.